Long-acting Drug Delivery in nAMD: Archway Phase 3 Results

The pivotal phase 3 Archway trial (NCT03677934) investigated the safety and efficacy of the Port Delivery System with ranibizumab (PDS) for the treatment of neovascular age-related macular degeneration. It compared the PDS with ranibizumab 100 mg/mL with refill-exchanges every 24 weeks versus monthly intravitreal ranibizumab 0.5 mg injections. The primary endpoint was change in best-corrected visual acuity score from baseline averaged over weeks 36 and 40. Primary analysis results, including the percentage of patients with 20/40 or better vision over time, are reported herein.

{{assetTitle}}

Authors {{assetAuthors}}

Published date{{formattedPublishDate}}

{{assetDescription}}

Welcome to Medically

The Roche Science Hub

This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.

Not a healthcare professional? Browse:

This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.